Medications for Opioid Use Disorder - For Healthcare and Addiction Professionals

Description: Medications for Opioid Use Disorder - For Healthcare and Addiction Professionals, Policymakers, Patients, and Families UPDATED 2021 (TIP 63) Brand new, full size and color TIP 63 Update As a reflection of SAMHSA’s commitment to ensuring that people with substance use disorders receive timely, relevant, high-quality care, SAMHSA in May 2021 revised certain areas of all five parts of this TIP to bring the content up to date and make it as useful to readers as possible. These changes will help provide readers with the latest information needed to understand medications for opioid use disorder. These changes include the following: • Updating statistics from SAMHSA, the Centers for Disease Control and Prevention, and other health authorities on opioid-related deaths, overdoses, accidents, and hospitalizations. Updating statistics from SAMHSA, the Centers for Disease Control and Prevention, and other health authorities on opioid-related deaths, overdoses, accidents, and hospitalizations. Updating the qualifications of practitioners who are eligible to apply for a waiver to prescribe buprenorphine (i.e., clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives) to include exceptions under the latest buprenorphine practice guidelines on obtaining a waiver.Where needed, clarifying whether references to naltrexone refer to the oral formulation or the extended-release injectable formulation. Adding recent citations that support induction onto extended-release naltrexone of people with positive urine tests for opioids so long as they pass the naloxone challenge.Clarifying that naltrexone can result in decreased opioid cravingsRemoving or replacing broken hyperlinks to online resources.

Price: 44.99 USD

Location: Agawam, Massachusetts

End Time: 2024-12-07T13:09:38.000Z

Shipping Cost: 0 USD